Switzerland’s Roche has jumped deeper into the allogeneic cell therapy space through an off-the-shelf CAR-T collaboration and license deal with Poseida Therapeutics. Pharma giant Roche’s adventure in the cell and gene space began with gene therapies, acquiring Spark Therapeutics in 2019 for $4.3 billion and instantly adding one of just a handful of approved products. Luxturna (voretigene neparvovec), a one-time gene therapy for an inherited retinal disease, was approved by the US Food and Drug Administration (FDA) in December 2017. Having…

The combination of the two cell and gene therapy CDMOs brings customers a transatlantic footprint and combined expertise, the companies say. UK-based cell therapy contract development and manufacturing organisation (CDMO) RoslinCT – a spinout from the Roslin Institute – has entered into a business combination agreement with Massachusetts-based Lykan Bioscience to merge. “The combination will create a global leader in process development and GMP manufacturing of advanced cell and gene therapies with transatlantic footprint in the US and UK,” a…